Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer.
about
Regression of murine lung tumors by the let-7 microRNAInternational Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesInsights into bombesin receptors and ligands: Highlighting recent advancesInteraction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancerResponses of cultured human keratocytes and myofibroblasts to ethyl pyruvate: a microarray analysis of gene expressionBradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon.Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic MiceGastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cellsATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage.Identifying potential tumor markers and antigens by database mining and rapid expression screeningHGF-independent potentiation of EGFR action by c-MetCombining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancerFunctional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma.RET rearrangements in lung adenocarcinoma and radiationTherapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesisInsulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis.AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.Augmented Responses to Ozone in Obese Mice Require IL-17A and Gastrin-releasing Peptide.A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.
P2860
Q24621218-87A644D8-C176-4888-9F02-4B0ED0294002Q24643524-F1746EC4-8A8A-4461-B93C-98EAC98DEE48Q28081153-D46D56F6-846F-4324-B340-F12F0EB82954Q33648356-96DAB425-C645-462E-99F3-90E55367653CQ33938175-4304AFB8-BAA7-4F20-B0BC-8648B4A2B004Q34049264-86133ABB-0CBE-4979-BDD7-4822FD53598FQ34365380-30B833E1-2ADD-4757-8AA9-F272047D5D73Q34627751-036A27BA-1917-4DE9-8A09-24A370CE3C39Q34768400-5E9F8351-D5D6-40E9-88CA-47CA0CF82D15Q34987777-4D88ADB7-B252-4D12-A1F6-1DBF1289CB1EQ35027517-CBC28AD1-1445-453E-B147-9261E92CB0CDQ35078530-EAA710C0-13F4-4BFB-AE43-A765B0E98CC1Q35784523-50CDB394-C502-45CE-9727-CF1D440E1881Q35799909-82AD7396-9274-43A6-A130-477B7A5F8F7AQ35834454-C3F8168C-AFF6-433C-8FD8-120AAFE210ACQ36276948-C777108A-DFBC-46B9-8CD5-5C8A167A7F31Q36557052-1EAA3502-C638-49A5-8D84-C416E4DB9F78Q36811473-5CC09AC3-94EA-4FE5-AA86-5DC6E42A3341Q36915616-BED4C7B3-435B-4CDA-A783-2405E9CBCDC1Q37161785-7EF24710-D93C-4D9B-9B0C-413AE0439694Q37294585-5D48C7E7-7506-4BBB-AA2D-9BFAE326EA02Q37333041-3E8DC8D6-6306-4048-915A-957D81AECF7AQ37480658-2DD38CFB-625D-4BAA-A1E9-819D0441B008Q37579308-BCC25E16-5573-4454-9474-3A0B8EEC165FQ38972229-40245822-F79D-4A8B-B660-0042C917F74CQ40003185-4D26E3FC-1F4A-4525-9B81-A04332FA2867Q40627909-606299C7-8351-4BC8-9B4C-D8C5FFE62329Q41074447-0879AC11-46E9-4F69-8B94-7681364D6052Q41323772-7E3AE61D-51F5-45F3-B7C8-58A9DD3F0CD6Q44737495-F883F791-166F-413C-912A-B68381517D4CQ44797073-1010D22F-7894-407F-8422-73AC253983EFQ47907010-5CE1121B-7D1B-4E24-ACF1-0CC858785DE2Q50149052-0BCE0748-D38C-4426-A4EA-52A5692627CC
P2860
Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Evidence for autocrine actions ...... in non-small cell lung cancer.
@en
type
label
Evidence for autocrine actions ...... in non-small cell lung cancer.
@en
prefLabel
Evidence for autocrine actions ...... in non-small cell lung cancer.
@en
P2093
P356
P1476
Evidence for autocrine actions ...... in non-small cell lung cancer.
@en
P2093
Gaither Davis A
Krishnamachary N
Shriver SP
Siegfried JM
P304
P356
10.1006/PUPT.1999.0210
P577
1999-01-01T00:00:00Z